Caladrius Biosciences Inc
LSE:0HS8
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.1679
3.679
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one 0HS8 stock under the Base Case scenario is 1.8633 USD. Compared to the current market price of 2.7197 USD, Caladrius Biosciences Inc is Overvalued by 31%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Caladrius Biosciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for 0HS8 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Caladrius Biosciences Inc
Balance Sheet Decomposition
Caladrius Biosciences Inc
Current Assets | 37.7m |
Cash & Short-Term Investments | 35.9m |
Other Current Assets | 1.8m |
Non-Current Assets | 507k |
PP&E | 278k |
Intangibles | 210k |
Other Non-Current Assets | 19k |
Current Liabilities | 4.7m |
Accounts Payable | 556k |
Accrued Liabilities | 4.1m |
Non-Current Liabilities | -182k |
Other Non-Current Liabilities | -182k |
Earnings Waterfall
Caladrius Biosciences Inc
Revenue
|
0
USD
|
Operating Expenses
|
-23.5m
USD
|
Operating Income
|
-23.5m
USD
|
Other Expenses
|
2.7m
USD
|
Net Income
|
-20.7m
USD
|
Free Cash Flow Analysis
Caladrius Biosciences Inc
USD | |
Free Cash Flow | USD |
0HS8 Profitability Score
Profitability Due Diligence
Caladrius Biosciences Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Caladrius Biosciences Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
0HS8 Solvency Score
Solvency Due Diligence
Caladrius Biosciences Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Caladrius Biosciences Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
0HS8 Price Targets Summary
Caladrius Biosciences Inc
According to Wall Street analysts, the average 1-year price target for 0HS8 is 14.1226 USD with a low forecast of 12.9854 USD and a high forecast of 15.5764 USD.
Dividends
Current shareholder yield for 0HS8 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.
Contact
IPO
Employees
Officers
The intrinsic value of one 0HS8 stock under the Base Case scenario is 1.8633 USD.
Compared to the current market price of 2.7197 USD, Caladrius Biosciences Inc is Overvalued by 31%.